Key result
Real-world HF patients receive ~42% lower sacubitril/valsartan doses than observed in PARADIGM-HF.
Why the study?
Does sacubitril/valsartan dosing and tolerability in real-world HFrEF patients differ from the PARADIGM-HF trial population?
Observational (n=120)
No
Does sacubitril/valsartan dosing and tolerability in real-world HFrEF patients differ from the PARADIGM-HF trial population?
Absolute Event Rate: 219% vs 375%
p-value: p=<0.001
Real-world HFrEF patients prescribed sacubitril/valsartan have more severe disease than trial populations, leading to lower achieved doses and greater blood pressure drops, though they still receive equipotent RAS inhibition.
No takes yet. Share an insight, caveat, or question.
Real-world HFrEF patients may tolerate lower sacubitril/valsartan doses; leaves open optimal dosing and outcome impact outside trials.
Martens et al. (2018) conducted an observational in Heart failure with reduced ejection fraction (HFrEF) (n=120). Sacubitril/valsartan vs. PARADIGM-HF trial population was evaluated on Achieved dose of sacubitril/valsartan (p=<0.001). Real-world heart failure patients exhibited more severe baseline disease and received a significantly lower dose of sacubitril/valsartan compared to the PARADIGM-HF trial population (219 vs 375 mg).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: